AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The OPTIMISE-CKD Study, officially titled A Multinational, Observational, Retrospective, Secondary Data Study Describing Management and Treatment in Routine Clinical Practice Among Patients With Chronic Kidney Disease. Local Adaptation for Spain. Part 1, aims to evaluate the management and treatment of chronic kidney disease (CKD) in Spain. The study focuses on assessing the incidence of renal disease using laboratory measurements and diagnostic codes, as well as the occurrence of cardiovascular and renal events and the use of kidney-protective treatments.
Intervention/Treatment: The study examines two cohorts: the Pre-pricing & reimbursement cohort and the Post-pricing & reimbursement cohort. These cohorts include patients with newly diagnosed renal disease, identified through laboratory measurements or CKD diagnosis, to understand the impact of pricing and reimbursement on treatment practices.
Study Design: This observational study uses a retrospective cohort model to analyze secondary data. It does not involve any direct intervention, and its primary purpose is to observe and describe current clinical practices in CKD management.
Study Timeline: The study began on August 1, 2020, with a primary completion date of February 1, 2023, for the pre-pricing cohort. The post-pricing cohort observation period extends until 2024. The last update was submitted on October 9, 2025, indicating the study’s completion.
Market Implications: This study’s findings could influence AstraZeneca’s stock performance by providing insights into CKD management practices and the effectiveness of kidney-protective treatments. Investors may view the study’s completion as a positive indicator of AstraZeneca’s commitment to addressing CKD, potentially impacting investor sentiment and positioning the company favorably against competitors in the renal disease treatment market.
The study is completed, and further details can be accessed on the ClinicalTrials portal.